BRD3-BD1 and 3.1C

3D Model

In recent years, cyclic peptides have been explored as treatment drugs because of their size, specificity, non-toxicity, and resistance to destruction by enzymes. A team of scientists in 2020 created 3.1C, an artificial cyclic peptide which acts as an inhibitor against BRD3-BD1. This is one of the BET (bromodomain and extraterminal domain) proteins, which are involved in the transcription of genes related to carcinogenesis. 3.1C has demonstrated a high affinity and selectivity for BRD3-BD1 due to its ability to bind in multiple different ways to the protein, allowing it to interact with BRD3-BD1 specifically and not with other BET proteins.

Sources:

https://tinyurl.com/mrxr27fd

https://tinyurl.com/yc5wae9v

https://tinyurl.com/yc5wedsw

https://tinyurl.com/y846wbhs